Sanofi signs diabetes research agreement with Brigham and Women’s
Sanofi SA, the French drug giant that bought Cambridge-based Genzyme Corp. for $20.1 billion last year, announced a new research collaboration with Brigham and Women’s Hospital, a teaching and research affiliate of Harvard Medical School. The collaboration is focused on the immunology of type 1 diabetes. Under the agreement, researchers from both organizations will undertake studies for a novel approach to treat type 1 diabetes. Sanofi has an option to exclusively license intellectual property emerging from this collaboration.